 |
|
|
| |
Risk of end-stage renal disease among hepatitis C patients with chronic kidney
disease treated with and without sofosbuvir
|
| |
| |
EASL 2020 virtual Aug 27-29
Reported by Jules Levin
Laura E. Telep1,2, Meghan Sise3, Lindsey Force1, Anuj Gaggar1, Anand P. Chokkalingam1,2
1 Gilead Sciences, Foster City, CA USA; 2 School of Public Health, University of California, Berkeley, CA, USA;
3 Department of Medicine, Division of Nephrology, Massachusetts General Hospital, Boston, MA, USA
|
| |
|
|
|
|
|
